Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.40 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077105 | 0.88 | CRHR1 (0.39) | CRHR1CNR1 | |
| SCHEMBL2871915 | 0.88 | CRHR1 (0.39) | CRHR1CDC7DBF4CCNT1CSNK2A2 | |
| SCHEMBL2871913 | 0.88 | CRHR1 (0.39) | CRHR1CDC7DBF4CCNT1CSNK2A2 | |
| SCHEMBL2861057 | 0.87 | CRHR1 (0.39) | CRHR1CDC7DBF4CCNT1CSNK2A2 | |
| SCHEMBL2869314 | 0.79 | CNR1 (0.46) | CRHR1CDC7DBF4CNR1 | |
| Hydrochloric Acid SCHEMBL2871081 | 0.78 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL2872388 | 0.77 | CRHR1 (0.41) | CRHR1CNR1 | |
| SCHEMBL7085011 | 0.77 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL2871902 | 0.76 | CRHR1 (0.41) | CRHR1CDC7DBF4 | |
| SCHEMBL2868815 | 0.76 | CSNK1E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772249-B2 | Imidazo[1,2-b]pyridazine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-09-21 | — | — | US | disclosed |
| US-7078405-B2 | Imidazo[1,2-b]pyridazine compound | EISAI CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1364952-A1 | BICYCLIC NITROGENOUS FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | CRHR1 1/4885CDC7 1542/4885DBF4 1654/4885 |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | CRHR1 1/4885CDC7 1542/4885DBF4 1654/4885 |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | CRHR1, CRH, CRHR2 | CRHR1 1/4885CDC7 1891/4885DBF4 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.